Tag: exposure-response

Documentation of PK/PD Analyses in CSR and Labeling Negotiations Documentation of PK/PD Analyses in CSR and Labeling Negotiations In the context of clinical trials, particularly those that focus on pharmacokinetics (PK) and pharmacodynamics (PD), the documentation of these analyses within Clinical Study Reports (CSRs) and subsequent labeling negotiations is paramount. These elements are crucial not…

Read More “Documentation of PK/PD Analyses in CSR and Labeling Negotiations” »

Regulatory Expectations for PK/PD Modeling in US, EU and Japan Regulatory Expectations for PK/PD Modeling in US, EU and Japan In the rapidly evolving landscape of clinical research, Pharmacokinetic/Pharmacodynamic (PK/PD) modeling has emerged as a pivotal tool for optimizing drug development across different therapeutic areas. Particularly within the realms of prostate cancer, schizophrenia, and various…

Read More “Regulatory Expectations for PK/PD Modeling in US, EU and Japan” »

Case Studies: PK/PD Analyses That Rescued or Repositioned Programs Case Studies: PK/PD Analyses That Rescued or Repositioned Programs Pharmacokinetics (PK) and pharmacodynamics (PD) play crucial roles in the design and analysis of clinical trials. This article provides a comprehensive step-by-step tutorial on case studies of PK/PD analyses that have significantly impacted clinical programs, particularly in…

Read More “Case Studies: PK/PD Analyses That Rescued or Repositioned Programs” »

Software Platforms and Workflows for PK/PD and Exposure-Response Software Platforms and Workflows for PK/PD and Exposure-Response In modern clinical research, particularly for complex therapeutic areas such as prostate cancer, effective software platforms and workflows for pharmacokinetics (PK), pharmacodynamics (PD), and exposure-response analysis are crucial for successful trial outcomes. This guide offers a structured approach to…

Read More “Software Platforms and Workflows for PK/PD and Exposure-Response” »

Integrating Biomarkers and Translational Data Into Exposure-Response Models In the evolving landscape of clinical trials, the integration of biomarkers and translational data into exposure-response (ER) models is becoming increasingly critical. This comprehensive guide focuses on the methodologies and regulatory guidelines for clinical operations, regulatory affairs, and medical affairs professionals in the US, UK, and EU….

Read More “Integrating Biomarkers and Translational Data Into Exposure-Response Models” »

PK/PD Considerations in DCT, Home Dosing and Remote Sampling PK/PD Considerations in DCT, Home Dosing and Remote Sampling Pharmacokinetics (PK) and pharmacodynamics (PD) play vital roles in clinical trials, particularly within the evolving landscape of decentralized clinical trials (DCTs). With the advent of remote sampling and home dosing, clinical operations must ensure that data quality…

Read More “PK/PD Considerations in DCT, Home Dosing and Remote Sampling” »

Integrating PK/PD Outputs Into Clinical and Regulatory Decision-Making Integrating PK/PD Outputs Into Clinical and Regulatory Decision-Making As the clinical research landscape continues to evolve, the integration of pharmacokinetic (PK) and pharmacodynamic (PD) outputs into clinical and regulatory decision-making has become critical. This is especially true for organizations conducting innovative clinical trials such as sanofi clinical…

Read More “Integrating PK/PD Outputs Into Clinical and Regulatory Decision-Making” »

Model-Based Dose Finding in Oncology, Rare Disease and Pediatrics In the realm of clinical trials and drug development, particularly within oncology, rare diseases, and pediatrics, model-based dose finding stands as a fundamental approach to determining optimal drug dosages while minimizing patient risk. This systematic method incorporates pharmacokinetics (PK) and pharmacodynamics (PD) principles, enabling researchers and…

Read More “Model-Based Dose Finding in Oncology, Rare Disease and Pediatrics” »

Nonlinear Mixed-Effects Models: Practical Considerations for Teams Nonlinear mixed-effects models (NLME) have become a cornerstone of pharmacokinetic (PK), pharmacodynamic (PD), and exposure-response modeling in clinical trials. As such, a strong understanding of these models is essential for clinical operations, regulatory affairs, and medical affairs professionals involved in clinical trial solutions. This article outlines a step-by-step…

Read More “Nonlinear Mixed-Effects Models: Practical Considerations for Teams” »

Handling Sparse and Rich PK Sampling in Global Clinical Trials Handling Sparse and Rich PK Sampling in Global Clinical Trials Introduction to Pharmacokinetics and Clinical Trials Pharmacokinetics (PK) is a vital component in the development and regulation of pharmaceuticals. It describes the absorption, distribution, metabolism, and excretion (ADME) of drugs within the body, providing critical…

Read More “Handling Sparse and Rich PK Sampling in Global Clinical Trials” »